Menopausal Hormone Therapy and Risk of Endometrial Carcinoma Among Postmenopausal Women in the European Prospective Investigation into Cancer and Nutrition
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Estrogen-only menopausal hormone therapy (HT) increases the risk of endometrial cancer, but less is known about the association with other types of HT. Using Cox proportional hazards regression, the authors examined the association of various types of HT with the risk of endometrial cancer among 115,474 postmenopausal women recruited into the European Prospective Investigation into Cancer and Nutrition between 1992 and 2000. After a mean follow-up period of 9 years, 601 incident cases of endometrial cancer were identified. In comparison with never users of HT, risk of endometrial cancer was increased among current users of estrogen-only HT (hazard ratio (HR) = 2.52, 95% confidence interval (CI): 1.77, 3.57), tibolone (HR = 2.96, 95% CI: 1.67, 5.26), and, to a lesser extent, estrogen-plus-progestin HT (HR = 1.41, 95% CI: 1.08, 1.83), although risks differed according to regimen and type of progestin constituent. The association of HT use with risk was stronger among women who were older, leaner, or had ever smoked cigarettes. The finding of a strong increased risk of endometrial cancer with estrogen-only HT and a weaker association with combined HT supports the hypothesis that progestins have an attenuating effect on endometrial cancer risk. The increased risk associated with tibolone use requires further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Riboli, E., Hunt, K., Slimani, N., Ferrari, P., Norat, T., Fahey, M., Charrondière, U., Hémon, B., Casagrande, C., Vignat, J., et al. (2002) · Public Health Nutrition · doi:10.1079/phn2002394 · Cited by 1,866 · cited 1×
“The cohort population and data collection procedures have been described in detail elsewhere (8).”
MethodSelf-citationFournier, A., Berrino, F., & Clavel-Chapelon, F. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9523-x · Cited by 693 · cited 1×
“Results from the E3N cohort study in France showed that progesterone-containing HT was more weakly associated with breast cancer risk than was HT containing other progestins (30), and it is conceivable that this weaker prostagenic effect could also apply to the endometrium, whereby micronized progesterone is not as ef…”
BackgroundSelf-citationAll progestins are not created equal
Stanczyk, F. Z. (2003) · Steroids · doi:10.1016/j.steroids.2003.08.003 · Cited by 226
Cited by
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Endometrial cancer: A review and current management strategies: Part II
Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B., Brewer, M., Boruta, D., Herzog, T. J., & Shahin, F. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.06.003 · Cited by 459
Stanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
Hormone replacement therapy and the risk of breast cancer
Narod, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.110 · Cited by 178
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
Metadata
- Authors
- Allen, N. E., Tsilidis, K. K., Key, T. J., Dossus, L., Kaaks, R., Lund, E., Bakken, K., Gavrilyuk, O., Overvad, K., Tjonneland, A., Olsen, A., Fournier, A., Fabre, A., Clavel-Chapelon, F., Chabbert-Buffet, N., Sacerdote, C., Krogh, V., Bendinelli, B., Tumino, R., Panico, S., Bergmann, M., Schuetze, M., van Duijnhoven, F. J. B., Bas Bueno-de-Mesquita, H., Charlotte Onland-Moret, N., van Gils, C. H., Amiano, P., Barricarte, A., Chirlaque, M.-D., Molina-Montes, M.-E., Redondo, M.-L., Duell, E. J., Khaw, K.-T., Wareham, N., Rinaldi, S., Fedirko, V., Mouw, T., Michaud, D. S., & Riboli, E.
- Venue
- American Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10-20
- Volume
- 172
- Issue
- 12
- Pages
- 1394-1403
- ISSN
- 0002-9262 (ISSN-L)
- 1476-6256
- OpenAlex
- W2114789422
- Cited by
- 141
- References
- 4
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.